TI
ELVN icon

Tidal Investments’s Enliven Therapeutics ELVN Stock Holding History

Tidal Investments’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.08M Buy
60,694
+13,179
+28% +$559K 0.01% 1153
2026
Q1 		$1.86M Buy
+47,515
New +$1.32M ﹤0.01% 1171
2024
Q3 		– Sell
-17,580
Closed -$411K – 1876
2024
Q2 		$411K Buy
+17,580
New +$370K 0.01% 1397

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Tidal Investments's ELVN Position: Q2 2026 in Review

Tidal Investments increased its Enliven Therapeutics (ELVN) stake by 28% in Q2 2026, buying an estimated $559K and bringing the position to 60,694 shares worth $3.08M. The position accounts for 0.01% of the portfolio, ranked #1153.

Tidal Investments first reported a position in ELVN in Q2 2024 and has held it in 3 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Tidal Investments held 60,694 shares of Enliven Therapeutics worth $3.08M as of Q2 2026.
  • Tidal Investments bought 13,179 Enliven Therapeutics shares in Q2 2026, an estimated $559K.
  • Enliven Therapeutics made up 0.01% of Tidal Investments's portfolio in Q2 2026, its #1153 holding.
  • Tidal Investments first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Tidal Investments's 13F filing for Q2 2026, filed 13 Aug 2026.